Prudential Financial Inc. Sells 15,700 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Prudential Financial Inc. trimmed its position in AxoGen, Inc. (NASDAQ:AXGN) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 418,285 shares of the medical equipment provider’s stock after selling 15,700 shares during the period. Prudential Financial Inc.’s holdings in AxoGen were worth $6,893,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of AXGN. Quest Partners LLC raised its holdings in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 2,076 shares during the period. Intech Investment Management LLC acquired a new stake in AxoGen during the 3rd quarter worth $173,000. Charles Schwab Investment Management Inc. lifted its holdings in AxoGen by 8.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 363,764 shares of the medical equipment provider’s stock worth $5,100,000 after acquiring an additional 28,659 shares in the last quarter. FMR LLC grew its stake in AxoGen by 743.1% in the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after acquiring an additional 157,730 shares during the period. Finally, Quantbot Technologies LP acquired a new position in AxoGen in the third quarter valued at about $165,000. Institutional investors own 80.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AXGN shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Lake Street Capital initiated coverage on shares of AxoGen in a research note on Monday, March 17th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Canaccord Genuity Group increased their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AxoGen has an average rating of “Buy” and an average target price of $22.60.

Insider Transactions at AxoGen

In other AxoGen news, insider Erick Wayne Devinney sold 15,111 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the transaction, the insider now directly owns 217,762 shares in the company, valued at $3,810,835. This trade represents a 6.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. This represents a 4.86 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

AxoGen Trading Down 3.3 %

NASDAQ:AXGN opened at $18.36 on Monday. The company has a market cap of $814.16 million, a P/E ratio of -57.38 and a beta of 1.02. AxoGen, Inc. has a twelve month low of $5.55 and a twelve month high of $21.00. The business has a 50 day moving average price of $18.27 and a two-hundred day moving average price of $15.86. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.